{"schema_version":"1.0","hypothesis_id":39980,"triple":{"drug":"Empagliflozin","drug_canonical":"empagliflozin","mediator":"AMPK","mediator_canonical":"AMPK","outcome":"epileptiform network activity","outcome_canonical":"epileptiform network activity"},"domain":{"domain":"cross_domain","source":"type_2_diabetes","target":"epilepsy"},"provenance_completeness":"partial_backfill","completeness_notes":"Backfilled retroactively from DB state on 2026-05-13. The pipeline_run this row references was created by the backfill script, not by the actual generation orchestrator. Source papers, claims, scoring, and embedding config are recovered; generation-time metadata (exact git commit at gen time, host, exact command) is not recoverable.","source_papers":[{"doi":"10.1161/jaha.124.040093","pmid":"40767292","year":2025,"roles":["drug_mediator"],"title":"Sodium Glucose Transporter 2 Inhibitor Protects Against Heart Failure With Preserved Ejection Fraction: Preclinical “2‐Hit” Model Reveals Autophagy Enhancement Via AMP‐Activated Protein Kinase/Mammalian Target of Rapamycin Complex 1 Pathway","journal":"J Am Heart Assoc","work_id":241882,"publication_date":"2025-08-06"},{"doi":"10.3390/ijms241210016","pmid":"37373164","year":2023,"roles":["drug_mediator"],"title":"Empagliflozin Attenuates Vascular Calcification in Mice with Chronic Kidney Disease by Regulating the NFR2/HO-1 Anti-Inflammatory Pathway through AMPK Activation","journal":"Int J Mol Sci","work_id":249431,"publication_date":"2023-06-12"},{"doi":"10.3389/fphys.2022.817542","pmid":"35299662","year":2022,"roles":["drug_mediator"],"title":"Empagliflozin Inhibits Hepatic Gluconeogenesis and Increases Glycogen Synthesis by AMPK/CREB/GSK3β Signalling Pathway","journal":"Front Physiol","work_id":238846,"publication_date":"2022-03-01"},{"doi":"10.3390/antiox11112152","pmid":"36358524","year":2022,"roles":["drug_mediator"],"title":"Effect of Empagliflozin on Thioacetamide-Induced Liver Injury in Rats: Role of AMPK/SIRT-1/HIF-1α Pathway in Halting Liver Fibrosis","journal":"Antioxidants (Basel)","work_id":236712,"publication_date":"2022-10-30"},{"doi":"10.1093/brain/awac037","pmid":"35134125","year":2022,"roles":["mediator_outcome"],"title":"AMPK-mediated potentiation of GABAergic signalling drives hypoglycaemia-provoked spike-wave seizures","journal":"Brain","work_id":40553,"publication_date":"2022-02-01"},{"doi":"10.7150/ijbs.33007","pmid":"32015688","year":2020,"roles":["drug_mediator"],"title":"Empagliflozin Attenuates Hyperuricemia by Upregulation of ABCG2 via AMPK/AKT/CREB Signaling Pathway in Type 2 Diabetic Mice","journal":"Int J Biol Sci","work_id":233884,"publication_date":"2020-01-01"},{"doi":"10.1002/jcb.28141","pmid":"30474134","year":2018,"roles":["drug_mediator"],"title":"Effect of sodium‐glucose cotransporter 2 inhibitor, empagliflozin, and α‐glucosidase inhibitor, voglibose, on hepatic steatosis in an animal model of type 2 diabetes","journal":"J Cell Biochem","work_id":243193,"publication_date":"2018-11-26"},{"doi":"10.1016/j.redox.2017.12.019","pmid":"29306791","year":2017,"roles":["drug_mediator"],"title":"Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission","journal":"Redox Biol","work_id":232059,"publication_date":"2017-12-30"}],"source_paper_count":8,"extracted_claims":[{"side":"drug_mediator","object":"AMPK","context":"in diabetic myocardial microvascular injury","subject":"empagliflozin","work_id":232059,"claim_id":164310,"polarity":"positive","predicate":"activates","confidence":0.7,"extraction_run_id":26},{"side":"drug_mediator","object":"AMPK","context":"in kidney and ileum of T2DM mice and HK-2 cells","subject":"Empagliflozin","work_id":233884,"claim_id":169102,"polarity":"positive","predicate":"activates","confidence":0.9,"extraction_run_id":27},{"side":"drug_mediator","object":"AMPK","context":"in liver of thioacetamide-treated rats","subject":"Empagliflozin","work_id":236712,"claim_id":176036,"polarity":"positive","predicate":"upregulates","confidence":0.9,"extraction_run_id":27},{"side":"drug_mediator","object":"AMPK","context":"in db/db mice and HL7702 cells","subject":"empagliflozin","work_id":238846,"claim_id":180928,"polarity":"positive","predicate":"activates","confidence":0.85,"extraction_run_id":27},{"side":"drug_mediator","object":"AMPK","context":"in HFpEF mouse model and H9c2 cardiomyocytes","subject":"empagliflozin","work_id":241882,"claim_id":187327,"polarity":"positive","predicate":"activates","confidence":0.85,"extraction_run_id":27},{"side":"drug_mediator","object":"AMPK","context":"in liver of OLETF rats","subject":"empagliflozin","work_id":243193,"claim_id":190655,"polarity":"positive","predicate":"activates","confidence":0.8,"extraction_run_id":27},{"side":"drug_mediator","object":"AMPK","context":"in mice with chronic kidney disease on a high-phosphate diet","subject":"Empagliflozin","work_id":249431,"claim_id":204545,"polarity":"positive","predicate":"activates","confidence":0.8,"extraction_run_id":27},{"side":"mediator_outcome","object":"epileptiform network activity","context":"in thalamic brain slices","subject":"AMPK","work_id":40553,"claim_id":22912,"polarity":"positive","predicate":"increases","confidence":0.8,"extraction_run_id":14}],"extracted_claim_count":8,"extraction":{"model":"deepseek-v4-flash","model_source":"configured","prompt_version":"v1_2026_05_07","run_ids":[14,26,27]},"bridge":{"a_to_b_predicate":"activates","b_to_c_predicate":"increases","a_to_b_evidence_count":7,"b_to_c_evidence_count":1,"edge_support_log_ab":2.0794415416798357,"edge_support_log_bc":0.6931471805599453,"novelty_factor":1.0,"direct_a_to_c_count":0},"embedding":{"model":"bge-m3","dim":1024,"max_length":8192,"similarity_scores":{}},"scoring":{"method":"swanson_abc_log_evidence_with_novelty_penalty","formula":"score = min((log(ab+1) + log(bc+1)) * novelty / 10, 1.0); novelty = 1.0 if direct==0 else 0.7 / (direct+1)","score_raw":0.2772588722239781,"score":0.2772588722239781,"quality_tier":"high","quality_reason":null},"pipeline_run":{"id":4,"run_uuid":"eb8b7730-d92e-4cd5-95dd-95f6c5d62cc2","command":"scripts/backfill_provenance_v2.py:v2_2026_05_12","status":"completed","git_commit":"9996ffaa56e9b7cd5f677bd8203624c2c18aa000","host":"MacBook-Pro-Daniel96.local","started_at":"2026-05-12T21:35:53.363326+00:00","ended_at":"2026-05-12T21:43:41.903387+00:00","notes":"Retroactive provenance backfill on 2026-05-13 for snapshot v2_2026_05_12. Synthetic pipeline_runs row — original generation run records are lost (pre-date provenance schema). All recoverable fields populated from current DB state (claims, works, repurposing_hypotheses); pipeline_run record is synthetic, hence completeness='partial_backfill'.\nBackfilled 1,618 provenance rows. Source papers: avg=3.73, zero=0. Claims matched: avg=4.09, zero=0.\nRefreshed 1,618 provenance rows. Source papers: avg=3.73, zero=0. Claims matched: avg=4.09, zero=0.\nRefreshed 1,618 provenance rows. Source papers: avg=3.73, zero=0. Claims matched: avg=4.09, zero=0.","domains":["als","alzheimer","depression","epilepsy","glioblastoma","inflammatory_bowel_disease","multiple_sclerosis","pancreatic_cancer","rheumatoid_arthritis","type_2_diabetes"]},"generated_at":"2026-05-12T21:43:40.945575+00:00"}